Oct. 30, 2009 (PR Newswire) --
SOUTH SAN FRANCISCO, Calif., Oct. 30 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) today announced that the Anesiva 2009 Annual Meeting of Stockholders will be held on December 3, 2009 at 9:00 a.m. PST at 400 Oyster Point, Suite 107A, South San Francisco, California. Stockholders of record at the close of business on October 9, 2009 will be eligible to vote at the 2009 Annual Meeting of Stockholders. The definitive proxy statement for the 2009 Annual Meeting of Stockholders will be mailed to stockholders on or about November 6, 2009.
At the 2009 Annual Meeting of Stockholders the Anesiva stockholders will be asked to approve, among other proposals, the issuance of shares of Anesiva common stock in the merger (the "Merger") contemplated by the Agreement and Plan of Merger, dated August 4, 2009, among Anesiva, Arca Acquisition Corporation ("Arca"), a wholly-owned subsidiary of Anesiva, Arcion Therapeutics, Inc. ("Arcion") and, with respect to Articles V and IX only of the agreement, each of the Arcion stockholders listed on Schedule I thereto (the "Merger Agreement"). For more information regarding the proposals for the 2009 Annual Meeting of Stockholders please see the definitive proxy statement filed with the Securities and Exchange Commission on October 30, 2009.
"The definitive proxy statement has been filed with the Securities and Exchange Commission for our 2009 Annual Meeting of Stockholders and I encourage stockholders to review the filing and vote on the proposals," said Michael Kranda, President and Chief Executive Officer of Anesiva. Mr. Kranda continued "We are looking forward to presenting the merger to our stockholders and completing the proposed transaction with Arcion."
About Anesiva
Anesiva seeks to be a leader in the development and commercialization of novel pharmaceutical products for pain management. Anesiva's lead product candidate is Adlea, a novel small molecule formulation of capsaicin that is currently in development for the management of acute pain following orthopedic surgeries. Adlea has been shown in clinical trials to provide extended pain relief after only a single administration in multiple indications for site-specific, acute and chronic, moderate-to-severe pain.
Additional Information and Where to Find It
Anesiva has a filed a definitive proxy statement with the Securities and Exchange Commission (the "SEC") in connection with the 2009 Annual Meeting of Stockholders. Investors and security holders are urged to read the definitive proxy statement because it contains important information about the 2009 Annual Meeting of Stockholders. Investors and security holders may obtain free copies of this document and other documents filed with the SEC at the SEC's website at www.sec.gov.
